<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hutchinson-Gilford progeria syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hutchinson-Gilford progeria syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hutchinson-Gilford progeria syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wendy J Introne, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melissa A Merideth, MD, MPH, FACOG, FACMG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2502382052">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          LMNA
         </em>
         gene on chromosome 1q encodes prelamin A. Prelamin A is ultimately converted to lamin A, a critically important structural protein component of the nuclear lamina that stabilizes the nuclear membrane [
         <a href="#rid1">
          1
         </a>
         ]. Pathogenic variants of
         <em>
          LMNA
         </em>
         cause a group of degenerative disorders known as laminopathies, which include Hutchinson-Gilford progeria syndrome (HGPS; MIM #176670) and at least 12 known diseases. (See
         <a class="local">
          'Other laminopathies'
         </a>
         below.)
        </p>
        <p>
         Classic HGPS, frequently referred to as "progeria," is an exceedingly rare, fatal, autosomal dominant disorder characterized by accelerated aging that starts early in childhood with severe failure to thrive and progressive development of a characteristic facial appearance, alopecia, lipoatrophy, skeletal dysplasia, and atherosclerosis that results in myocardial infarction, stroke, and ultimately death in the second decade of life [
         <a href="#rid2">
          2
         </a>
         ]. Atypical progeria syndromes have been reported in the literature. While there is considerable overlap in the phenotype, variability remains in the severity, onset, and lifespan as compared with HGPS. Causative variants for atypical progeria have been reported in
         <em>
          LMNA
         </em>
         but are not the same as the classic G608G pathogenic variant in HGPS [
         <a href="#rid2">
          2
         </a>
         ]. The term "progeroid syndrome" is also more broadly used to refer to various rare disorders with features of premature aging, such as Werner syndrome, Cockayne syndrome, and Bloom syndrome.
        </p>
        <p>
         The pathogenesis, genetics, clinical characteristics, diagnosis, and management of classic HGPS
         <strong>
         </strong>
         are discussed here. Other laminopathies are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6185.html" rel="external">
          "Emery-Dreifuss muscular dystrophy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Familial partial lipodystrophy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Mandibuloacral dysplasia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1167212808">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare panethnic disorder, with an estimated incidence of one in four to eight million births [
         <a href="#rid3">
          3
         </a>
         ]. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.progeriaresearch.org%2F&amp;token=%2FydOckGcXt0QpwouWndQAYM0en4U1%2FfrI5FVhrbOvEOUxWbwXOOizIkl2qCKAAwU&amp;TOPIC_ID=106741" target="_blank">
          Progeria Research Foundation
         </a>
         estimates the prevalence of HGPS at 1 in 20 million [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4120308199">
         <span class="h1">
          GENETICS AND PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H3323678139">
         <span class="h2">
          Classic Hutchinson-Gilford progeria syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hutchinson-Gilford progeria syndrome (HGPS) is caused by a single nucleotide substitution in the lamin A/C gene
         <em>
          LMNA
         </em>
         (c.1824C&gt;T [p.Gly608Gly]), encoding two different types of protein isoforms (lamin A and lamin C) [
         <a href="#rid5">
          5,6
         </a>
         ].
         <em>
         </em>
         Although the pathogenic variant of
         <em>
          LMNA
         </em>
         does not change the encoded amino acid glycine, this single de novo C to T pathogenic variant at position 1824 of codon 608 of the
         <em>
          LMNA
         </em>
         gene activates a cryptic splice donor site. The splice donor site creates a messenger RNA with a 150-nucleotide internal deletion near the C-terminus.
        </p>
        <p>
         The mutation in HGPS causes production of a unique mutant lamin A protein called
         <strong>
          progerin
         </strong>
         , which has a 50-amino acid internal deletion. A missing cleavage site within this deletion leads to permanent farnesylation causing the progerin to remain anchored to the nuclear envelope. This permanently farnesylated state of progerin disrupts the normal organization of the nuclear lamina and is hypothesized to cause nuclear blebbing, disorganized heterochromatin, and dysregulated gene transcription. This genomic instability is thought to cause the premature aging and disease in HGPS. Telomere shortening in HGPS is an area of investigation. Average telomere length is decreased in HGPS fibroblasts [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2452344835">
         <span class="h2">
          Atypical progeria syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical progeria syndromes
         <strong>
         </strong>
         with similar clinical characteristics to classic HGPS
         <strong>
         </strong>
         are caused by a variety of pathogenic variants in intron 11 of the
         <em>
          LMNA
         </em>
         gene, rather than the classic (c.1824C&gt;T [p.Gly608Gly]) pathogenic variant in HGPS [
         <a href="#rid2">
          2,9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H790397893">
         <span class="h2">
          Other laminopathies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to HGPS, a broad range of diseases caused by
         <em>
          LMNA
         </em>
         gene mutations have been identified. These disorders are allelic:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mandibuloacral dysplasia (see
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Mandibuloacral dysplasia'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restrictive dermopathy, a rare, lethal neonatal laminopathy [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Familial partial lipodystrophy type 2 (see
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'FPLD type 2'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limb-girdle muscular dystrophy with atrioventricular conduction defects (LGMD1B) (see
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autosomal dominant dilated cardiomyopathy with conduction defects (CMD1A or DCM-CD) [
         <a href="#rid11">
          11
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/4911.html" rel="external">
          "Genetics of dilated cardiomyopathy", section on 'Autosomal dominant DCM with or without conduction system disease'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emery-Dreifuss muscular dystrophy (EDMD2 and EDMD3) (see
         <a class="medical medical_review" href="/z/d/html/6185.html" rel="external">
          "Emery-Dreifuss muscular dystrophy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dilated cardiomyopathy and hypergonadotropic hypogonadism (atypical Werner syndrome) [
         <a href="#rid12">
          12
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A relatively severe form of congenital muscular dystrophy classified as
         <em>
          LMNA
         </em>
         -related congenital muscular dystrophy [
         <a href="#rid13">
          13
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Charcot-Marie-Tooth type 2B1 [
         <a href="#rid14">
          14
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart-hand syndrome, Slovenian type [
         <a href="#rid15">
          15
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malouf syndrome with hypergonadotropic hypogonadism and cardiomyopathy [
         <a href="#rid16">
          16
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autosomal dominant dilated cardiomyopathy with apical left ventricular aneurysm [
         <a href="#rid17">
          17
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/4911.html" rel="external">
          "Genetics of dilated cardiomyopathy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autosomal dominant quadriceps myopathy with dilated cardiomyopathy and associated conduction defects [
         <a href="#rid18">
          18
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H572237212">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children affected with Hutchinson-Gilford progeria syndrome (HGPS) appear normal at birth, but the clinical manifestations become apparent in the first few years of life. These include failure to thrive; dermatologic, musculoskeletal, and neurologic abnormalities; and eventually life-limiting cardiovascular disease. Children with HGPS also have audiologic, dental, and ophthalmologic issues that impact their lives.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Failure to thrive
         </strong>
         – Despite adequate caloric intake, young children with HGPS have growth impairment, resulting in poor weight gain, short stature, and loss of subcutaneous fat [
         <a href="#rid19">
          19
         </a>
         ]. Sexual maturation is absent in most patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Facial features
         </strong>
         – Children with HGPS develop a characteristic facial appearance that includes circumoral cyanosis; prominent eyes; thin, beaked nose; micrognathia; retrognathia; thin lips; loss of eyebrows; and prominent scalp veins (
         <a class="graphic graphic_picture graphicRef132717" href="/z/d/graphic/132717.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid2">
          2,20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin changes
         </strong>
         – The skin changes include atrophy and dryness, with areas that appear taut and sclerotic and areas of laxity and outpouching; reticulated hyperpigmentation interspersed with hypopigmentation; and dimpling and mottling, especially over the abdomen and thighs (
         <a class="graphic graphic_picture graphicRef132719" href="/z/d/graphic/132719.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid22">
          22
         </a>
         ]. Young children with HGPS develop alopecia and dystrophic fingernails and toenails [
         <a href="#rid2">
          2,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Musculoskeletal abnormalities
         </strong>
         – Musculoskeletal findings include progressive joint contractures, decreased joint range of motion, fingertip tufting, osteoarthritis, coxa valga, and a wide-based stance and shuffling gait [
         <a href="#rid2">
          2,20
         </a>
         ]. Endocrinologic abnormalities include decreased bone mineral density, lipodystrophy, and insulin resistance [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic abnormalities
         </strong>
         – Neurologic findings include intracranial and superior cervical arteriopathy, with evidence of early and clinically silent strokes seen in children as early as 5 to 10 years of age [
         <a href="#rid23">
          23
         </a>
         ]. Cognitive development and intellectual function are normal, and there is no evidence of dementia from limited autopsy studies [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular abnormalities
         </strong>
         – Cardiovascular findings include progressive reduced vascular function with age and progressive atherosclerosis, resulting in premature death from myocardial infarction or, less frequently, stroke, despite a lack of typical cardiovascular risk factors (eg, elevated cholesterol and C-reactive protein) [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dental abnormalities
         </strong>
         – Dental findings in children with HGPS include hypodontia (most often missing the second premolars), ogival arch, steep mandibular angles, ankyloglossia, dysmorphic teeth, delayed tooth eruption, and double rows of teeth (
         <a class="graphic graphic_picture graphicRef132718" href="/z/d/graphic/132718.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Otologic abnormalities
         </strong>
         – Otologic abnormalities include small or absent ear lobules, stiff auricular cartilages, and hypoplasia of the external ear canal soft tissue (leading to shortened canals) [
         <a href="#rid28">
          28
         </a>
         ]. Audiologically, patients with HGPS have low-frequency conductive hearing loss [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ocular abnormalities
         </strong>
         – Ophthalmologic issues include hyperopia, nocturnal lagophthalmos, and corneal dryness [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H761415486">
         <span class="h1">
          LABORATORY AND IMAGING FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hutchinson-Gilford progeria syndrome (HGPS) is associated with several laboratory and imaging abnormalities, including [
         <a href="#rid2">
          2,20,29,30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased serum leptin levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insulin resistance in up to one-half of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased bone density.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiographic findings of acro-osteolysis, clavicular resorption, and coxa valga.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other routine laboratory studies are generally unremarkable. Mild elevations in platelet and prolonged prothrombin time have been reported [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3381570343">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of Hutchinson-Gilford progeria syndrome (HGPS) is suspected in a child presenting with the following features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure to thrive in the first year of life
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Characteristic facial appearance with micrognathia, prominent eyes, and circumoral cyanosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alopecia and prominent scalp veins
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sclerotic skin changes with outpouching and dimpling/mottling, especially on the abdomen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased joint range of motion and joint contractures
        </p>
        <p>
        </p>
        <p>
         The diagnosis of HGPS is established based upon the presence of the clinical features listed above and the identification by genetic testing of the known causative pathogenic variant in the
         <em>
          LMNA
         </em>
         gene (c.1824C&gt;T[p.Gly608Gly]).
        </p>
        <p class="headingAnchor" id="H2471927012">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of classic Hutchinson-Gilford progeria syndrome (HGPS) includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical progeria syndromes
         </strong>
         – Atypical progeria syndromes, which have clinical features similar to classic HGPS, can be more or less severe and are caused by pathogenic variants in
         <em>
          LMNA
         </em>
         other than the classic G608G pathogenic variant [
         <a href="#rid2">
          2,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Restrictive dermopathy
         </strong>
         – Restrictive dermopathy (MIM #275210) is a genetic disease, typically lethal in the neonatal period, characterized by abnormally tight skin from birth caused by pathogenic variants in the genes encoding lamin A (
         <em>
          LMNA
         </em>
         ) and a zinc metalloproteinase (
         <em>
          ZMPSTE24
         </em>
         ) that processes lamin A [
         <a href="#rid32">
          32
         </a>
         ]. Affected newborns are usually premature and present with diffusely hard skin that may shear or tear at areas of skin folding, such as the neck, inguinal folds, and lower abdomen (
         <a class="graphic graphic_picture graphicRef112139 graphicRef110284" href="/z/d/graphic/112139.html" rel="external">
          picture 4A-B
         </a>
         ) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Familial partial lipodystrophy type 2
         </strong>
         – Familial partial lipodystrophy (FPLD) is a group of rare and genetically heterogeneous syndromes characterized by variable loss of adipose tissue that occurs during childhood, puberty, or young adulthood; metabolic abnormalities; and cardiomyopathy [
         <a href="#rid34">
          34
         </a>
         ]. FPLD type 2 (Dunnigan lipodystrophy, MIM #151660) is allelic to HGPS, as it is caused by pathogenic variants in the
         <em>
          LMNA
         </em>
         gene. (See
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Familial partial lipodystrophy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other rare progeroid syndromes with features of premature aging that should be differentiated by HGPS include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome) [
         <a href="#rid35">
          35
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital generalized lipodystrophy (see
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Congenital generalized lipodystrophy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cockayne syndrome (see
         <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">
          "Neuropathies associated with hereditary disorders", section on 'Cockayne syndrome'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mandibuloacral dysplasia [
         <a href="#rid36">
          36
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Petty-Laxova-Wiedemann progeroid syndrome [
         <a href="#rid37">
          37
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3216297889">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of Hutchinson-Gilford progeria syndrome (HGPS) is supportive and involves ensuring optimal nutrition, monitoring of disease progression, and treatment of complications as they present [
         <a href="#rid2">
          2
         </a>
         ].
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          Lonafarnib
         </a>
         , the only specific treatment for HGPS, was approved in 2020 by the US Food and Drug Administration for patients 12 months of age and older [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1856687896">
         <span class="h2">
          Lonafarnib
         </span>
         <span class="headingEndMark">
          —
         </span>
         In November 2020,
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          lonafarnib
         </a>
         , an oral farnesyltransferase inhibitor (FTI), was approved by the US Food and Drug Administration (orphan drug designation) for the treatment of HGPS in patients 12 months of age and older [
         <a href="#rid39">
          39
         </a>
         ]. Lonafarnib is administered orally twice daily with meals at a starting dose of 115 mg/m
         <sup>
          2
         </sup>
         . Adverse effects include vomiting, diarrhea, abdominal pain, infection, and fatigue.
        </p>
        <p>
         It is hypothesized that
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          lonafarnib
         </a>
         may inhibit the formation of the aberrant lamin A protein progerin and prevent its anchoring to the inner nuclear membrane, thus potentially improving disease status in HGPS [
         <a href="#rid40">
          40
         </a>
         ]. Studies supporting the use of lonafarnib for HGPS are summarized here:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A nonrandomized, clinical trial of
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          lonafarnib
         </a>
         in 25 children with HGPS provided some evidence of efficacy in reducing the carotid artery echodensity and improving the bone structure in these patients [
         <a href="#rid41">
          41
         </a>
         ]. In another study using lonafarnib as part of a triple-drug regimen with
         <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">
          zoledronic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         in 37 children, 26 (71 percent) achieved at least one of the primary composite outcomes (increase in per-patient rate of weight gain and/or decrease in carotid artery echodensity) [
         <a href="#rid42">
          42
         </a>
         ]. However, a cardiovascular benefit was not observed in this study.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent, nonrandomized study evaluated the effect of oral
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          lonafarnib
         </a>
         on all-cause mortality in a cohort of 27 patients (median age 8.4 years) with HGPS compared with 27 matched, untreated patients [
         <a href="#rid43">
          43
         </a>
         ]. The median treatment duration was 2.2 years. During this period, the observed mortality rate was 3.7 percent among patients receiving lonafarnib versus 33.3 percent in the untreated group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study using a single molecule counting immunoassay developed to detect the progerin protein in plasma from patients with HGPS showed that treatment with
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          lonafarnib
         </a>
         was associated with decreased plasma progerin levels and improved survival [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although these data are encouraging, the results of additional, ongoing studies are awaited before
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          lonafarnib
         </a>
         can be recommended for all children with HGPS. (See
         <a class="local">
          'Experimental therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H876734453">
         <span class="h2">
          Growth issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         A nutritional assessment, plotting of weight/height on growth charts, and frequent small meals to increase/maximize calorie intake are recommended [
         <a href="#rid2">
          2
         </a>
         ]. Attention to adequate oral hydration is important.
        </p>
        <p class="headingAnchor" id="H3966983138">
         <span class="h2">
          Cardiac and neurologic issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary concern in patients with HGPS is accelerated progressive atherosclerosis leading to myocardial infarction, transient ischemic attack (TIA), and stroke. The cardiac and neurologic status of the patient should be investigated, even in asymptomatic patients, at least once a year. Cardiovascular assessment should include electrocardiogram (ECG), blood pressure measurement, lipid profile testing, and echocardiography.
        </p>
        <p>
         Neurologic evaluation should include brain and neck magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA) and carotid duplex scans to assess vascular status [
         <a href="#rid2">
          2,24
         </a>
         ]. Although
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         has not been specifically studied in patients with HGPS, antiplatelet therapy may offer benefits to patients with cardiovascular and cerebrovascular disease similar to its use in adults [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">
          "Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3405709531">
         <span class="h2">
          Musculoskeletal issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skeletal radiographs are recommended after initial diagnosis. Dual-energy x-ray absorptiometry (DEXA) for assessment of bone mineral density (with values normalized for height) is recommended annually.
        </p>
        <p>
         Given the joint contractures associated with HGPS, standard goniometry for assessment of joint mobility is recommended, as is routine physical and occupational therapy. Patients with HGPS may benefit from orthotics, including shoe pads/inserts and hip braces in the setting of hip dysplasia [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3052011461">
         <span class="h2">
          Dental issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine dental evaluation (every six months) is recommended, with attention to the possible need for extraction of primary teeth to prevent overcrowding.
        </p>
        <p class="headingAnchor" id="H592988300">
         <span class="h2">
          Ophthalmologic issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ophthalmology evaluation is recommended annually to assess for possible exposure keratopathy. Patients with HGPS may benefit from the use of eye drops for corneal dryness and nighttime use of moisturizing ointment for nocturnal lagophthalmos [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3034066235">
         <span class="h2">
          Hearing issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Audiology evaluation is recommended annually to assess for possible low-frequency conductive hearing loss and consideration of hearing aids if needed.
        </p>
        <p class="headingAnchor" id="H3447876340">
         <span class="h2">
          Genetic counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the overwhelming majority of cases, HGPS occurs due to a de novo pathogenic variant (c.1824C&gt;T [p.Gly608Gly]). However, in extremely rare cases, somatic and germline mosaicism has been reported [
         <a href="#rid45">
          45
         </a>
         ]. For assessment of reproductive risk, genetics referral of affected families is recommended.
        </p>
        <p class="headingAnchor" id="H4067439324">
         <span class="h2">
          Medication dosing issues and anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medication doses should be based on body weight or body surface area rather than age. General anesthesia and intubation can be difficult in patients with HGPS due to narrow airways, necessitating the use of fiberoptic intubation [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3172212547">
         <span class="h1">
          EXPERIMENTAL THERAPIES
         </span>
        </p>
        <p class="headingAnchor" id="H1443731075">
         <span class="h2">
          Lonafarnib plus everolimus
         </span>
         <span class="headingEndMark">
          —
         </span>
         An ongoing clinical trial (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT02579044&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQcIast0TADsdxy9RFQzfVE1VnJIc7bAHKBHY54uNb1hQ%3D%3D&amp;TOPIC_ID=106741" target="_blank">
          NCT02579044
         </a>
         ) is investigating
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          lonafarnib
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         , an mTOR inhibitor. It is hypothesized that while lonafarnib inhibits the progerin formation, everolimus may help clear progerin from cells [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1625433746">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with classic Hutchinson-Gilford progeria syndrome (HGPS) develop progressive atherosclerosis, generally leading to death from myocardial infarction or stroke at the age of approximately 15 years [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2027980899">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Hutchinson-Gilford progeria syndrome (HGPS) is an exceedingly rare, autosomal dominant, premature aging disease. It is caused by a single nucleotide substitution in the
         <em>
          LMNA
         </em>
         gene, c.1824C&gt;T(p.Gly608Gly). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Genetics and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The onset of symptoms of HGPS usually occur in the first few years of life. The cardinal features include failure to thrive, loss of subcutaneous fat, poor weight gain, short stature, joint contractures, and accelerated progressive atherosclerosis leading to myocardial infarction, transient ischemic attacks, and stroke. Additional clinical features include atrophic skin changes with hyper/hypopigmentation, alopecia, and a characteristic facial appearance with circumoral cyanosis; prominent eyes; thin, beaked nose; micrognathia; retrognathia; and prominent scalp veins. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory and imaging findings
         </strong>
         – These include decreased bone mineral density, decreased serum leptin levels, insulin resistance, coxa valga, clavicular resorption, and acro-osteolysis. (See
         <a class="local">
          'Laboratory and imaging findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of HGPS is established based upon the presence of characteristic clinical features and the identification by genetic testing of the known causative pathogenic variant in the
         <em>
          LMNA
         </em>
         gene. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Management is supportive and involves ensuring optimal nutrition, monitoring of disease progression, and treatment of complications as they present.
         <a class="drug drug_general" data-topicid="130213" href="/z/d/drug information/130213.html" rel="external">
          Lonafarnib
         </a>
         , an oral farnesyltransferase inhibitor (FTI) that appears to inhibit the formation of the aberrant lamin A protein progerin, may improve disease status and survival in patients with HGPS. (See
         <a class="local">
          'Management'
         </a>
         above and
         <a class="local">
          'Lonafarnib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Patients with HGPS develop progressive atherosclerosis that eventually leads to death from myocardial infarction or stroke in the second decade of life. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Elzeneini E, Wickström SA. Lipodystrophic laminopathy: Lamin A mutation relaxes chromatin architecture to impair adipogenesis. J Cell Biol 2017; 216:2607.
          </a>
         </li>
         <li class="breakAll">
          Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford progeria syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 2006; 140:2603.
          </a>
         </li>
         <li class="breakAll">
          The Progeria Research Foundation. PRF by the numbers. www.progeriaresearch.org/wp-content/uploads/2018/01/PRF-By-the-Numbers_-Jan-2018-Update-1.pdf (Accessed on May 07, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992; 89:10114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decker ML, Chavez E, Vulto I, Lansdorp PM. Telomere length in Hutchinson-Gilford progeria syndrome. Mech Ageing Dev 2009; 130:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulson CL, Fong LG, Gardner JM, et al. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. Hum Mutat 2007; 28:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKenna T, Sola Carvajal A, Eriksson M. Skin Disease in Laminopathy-Associated Premature Aging. J Invest Dermatol 2015; 135:2577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra R, Mason PK. Lamin A/C deficiency as a cause of familial dilated cardiomyopathy. Curr Opin Cardiol 2009; 24:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen L, Lee L, Kudlow BA, et al. LMNA mutations in atypical Werner's syndrome. Lancet 2003; 362:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quijano-Roy S, Mbieleu B, Bönnemann CG, et al. De novo LMNA mutations cause a new form of congenital muscular dystrophy. Ann Neurol 2008; 64:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002; 70:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renou L, Stora S, Yaou RB, et al. Heart-hand syndrome of Slovenian type: a new kind of laminopathy. J Med Genet 2008; 45:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malouf J, Alam S, Kanj H, et al. Hypergonadotropic hypogonadism with congestive cardiomyopathy: an autosomal-recessive disorder? Am J Med Genet 1985; 20:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forissier JF, Bonne G, Bouchier C, et al. Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. Eur J Heart Fail 2003; 5:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charniot JC, Pascal C, Bouchier C, et al. Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. Hum Mutat 2003; 21:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon LB, McCarten KM, Giobbie-Hurder A, et al. Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics 2007; 120:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merideth MA, Gordon LB, Clauss S, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 2008; 358:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domingo DL, Trujillo MI, Council SE, et al. Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. Oral Dis 2009; 15:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang S, Yang Z, Xu Z, et al. Clinical and genetic features of children with Hutchinson-Gilford progeria syndrome: a case series and a literature review. J Eur Acad Dermatol Venereol 2021; 35:e387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silvera VM, Gordon LB, Orbach DB, et al. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol 2013; 34:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol 2015; 132:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olive M, Harten I, Mitchell R, et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010; 30:2301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerhard-Herman M, Smoot LB, Wake N, et al. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension 2012; 59:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen FJ, Gordon LB, Smoot L, et al. Progression of Cardiac Abnormalities in Hutchinson-Gilford Progeria Syndrome: A Prospective Longitudinal Study. Circulation 2023; 147:1782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guardiani E, Zalewski C, Brewer C, et al. Otologic and audiologic manifestations of Hutchinson-Gilford progeria syndrome. Laryngoscope 2011; 121:2250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon LB, Campbell SE, Massaro JM, et al. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. Pediatr Res 2018; 83:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleveland RH, Gordon LB, Kleinman ME, et al. A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. Pediatr Radiol 2012; 42:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultz B, Miller DD, Maguiness S. Diffuse, mottled hyperpigmentation and mutations in LMNA gene in a 5-year-old boy, his mother, and his grandmother: Atypical progeroid syndrome. Pediatr Dermatol 2019; 36:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro CL, Esteves-Vieira V, Courrier S, et al. New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update. Eur J Hum Genet 2014; 22:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smitt JH, van Asperen CJ, Niessen CM, et al. Restrictive dermopathy. Report of 12 cases. Dutch Task Force on Genodermatology. Arch Dermatol 1998; 134:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lightbourne M, Brown RJ. Genetics of Lipodystrophy. Endocrinol Metab Clin North Am 2017; 46:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paolacci S, Bertola D, Franco J, et al. Wiedemann-Rautenstrauch syndrome: A phenotype analysis. Am J Med Genet A 2017; 173:1763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cenni V, D'Apice MR, Garagnani P, et al. Mandibuloacral dysplasia: A premature ageing disease with aspects of physiological ageing. Ageing Res Rev 2018; 42:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delgado-Luengo WN, Petty EM, Solís-Añez E, et al. Petty-Laxova-Wiedemann progeroid syndrome: further phenotypical delineation and confirmation of a rare syndrome of premature aging. Am J Med Genet A 2009; 149A:2200.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA approves first treatment for Hutchinson-Gilford progeria syndrome and some progeroid laminopathies. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies (Accessed on October 27, 2023).
         </li>
         <li class="breakAll">
          Lonafarnib capsules, for oral use. US Food and Drug Administration (FDA) approved product information. Revised November 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf (Accessed on February 03, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capell BC, Erdos MR, Madigan JP, et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005; 102:12879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon LB, Kleinman ME, Miller DT, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2012; 109:16666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon LB, Kleinman ME, Massaro J, et al. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation 2016; 134:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon LB, Shappell H, Massaro J, et al. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA 2018; 319:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon LB, Norris W, Hamren S, et al. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation. Circulation 2023; 147:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wuyts W, Biervliet M, Reyniers E, et al. Somatic and gonadal mosaicism in Hutchinson-Gilford progeria. Am J Med Genet A 2005; 135:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DuBose AJ, Lichtenstein ST, Petrash NM, et al. Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc Natl Acad Sci U S A 2018; 115:4206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon LB, Massaro J, D'Agostino RB Sr, et al. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 2014; 130:27.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 106741 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28811278" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lipodystrophic laminopathy: Lamin A mutation relaxes chromatin architecture to impair adipogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28811278" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lipodystrophic laminopathy: Lamin A mutation relaxes chromatin architecture to impair adipogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16838330" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hutchinson-Gilford progeria syndrome: review of the phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16838330" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hutchinson-Gilford progeria syndrome: review of the phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702809" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lamin a truncation in Hutchinson-Gilford progeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12714972" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1438199" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Telomere length predicts replicative capacity of human fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19428457" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Telomere length in Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17469202" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26290387" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Skin Disease in Laminopathy-Associated Premature Aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384091" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lamin A/C deficiency as a cause of familial dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12927431" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : LMNA mutations in atypical Werner's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18551513" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : De novo LMNA mutations cause a new form of congenital muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11799477" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18611980" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Heart-hand syndrome of Slovenian type: a new kind of laminopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3993676" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hypergonadotropic hypogonadism with congestive cardiomyopathy: an autosomal-recessive disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14675861" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12673789" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17908770" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18256394" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Phenotype and course of Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19236595" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33590899" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical and genetic features of children with Hutchinson-Gilford progeria syndrome: a case series and a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23179651" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26564085" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798379" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22083160" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37276254" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Progression of Cardiac Abnormalities in Hutchinson-Gilford Progeria Syndrome: A Prospective Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21898437" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Otologic and audiologic manifestations of Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29342131" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22752073" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31378009" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Diffuse, mottled hyperpigmentation and mutations in LMNA gene in a 5-year-old boy, his mother, and his grandmother: Atypical progeroid syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24169522" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9606327" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Restrictive dermopathy. Report of 12 cases. Dutch Task Force on Genodermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28476236" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Genetics of Lipodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28447407" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Wiedemann-Rautenstrauch syndrome: A phenotype analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29208544" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mandibuloacral dysplasia: A premature ageing disease with aspects of physiological ageing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19725131" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Petty-Laxova-Wiedemann progeroid syndrome: further phenotypical delineation and confirmation of a rare syndrome of premature aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19725131" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Petty-Laxova-Wiedemann progeroid syndrome: further phenotypical delineation and confirmation of a rare syndrome of premature aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19725131" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Petty-Laxova-Wiedemann progeroid syndrome: further phenotypical delineation and confirmation of a rare syndrome of premature aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16129833" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23012407" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27400896" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29710166" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36919608" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15793835" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Somatic and gonadal mosaicism in Hutchinson-Gilford progeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29581305" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24795390" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
